Inovio up 7% after hours on encouraging COVID-19 vaccine data

Inovio Pharmaceuticals (NASDAQ:INO) is up 7% after hours in reaction to interim data (through week 16) from a Phase 1/2a clinical trial evaluating its COVID-19 MERS-CoV DNA vaccine candidate INO-4700 in healthy volunteers.

Recipients showed “strong antibody and T cell immune responses” after two or three doses with 0.6 mg of INO-4700 while being well-tolerated with no vaccine-related severe adverse events observed.

Specifically, 88% of recipients demonstrated seroconversion after a two-dose regimen administered eight weeks apart. 84% of recipients seroconverted after two doses (day 0, week 4) of a three-dose regimen while 100% seroconverted after three doses (last one at week 8).

The company says it plans to launch a Phase 2 study in the Middle East considering the vaccine’s performance against the MERS virus in a non-human primate model.

https://seekingalpha.com/news/3565668-inovio-up-7-after-hours-on-encouraging-covidminus-19-vaccine-data